Author

Shubo Zuo

Institution: Jilin Province Tumor Hospital

Observed institution: Jilin Province Tumor Hospital

ORCID: 0009-0008-2504-7119

Observed ORCID: 0009-0008-2504-7119

OpenAlex ID: A5023220132

Antitumor activity and safety of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma: An open-label, multicenter, phase II study

2023 · Yanfei Liu, Yuqin Song, et al. · Frontiers in Immunology · 5

Clinical Analysis of Five Cases of AIDS-relatedNon-Hodgkin Lymphoma

2016 · Shubo Zuo, Na Xu, et al. · Pakistan Journal of Medical Sciences · 2

The Dual Role of TLR2 in Breast Cancer: Implications for Therapeutic Targeting

2026 · Hao Yu, Yang Zhang, et al. · Immunological Investigations · 1

Multi‐omics molecular phenotyping reveals the potential mechanisms of chemotherapy response and resistance in small cell lung cancer

2024 · Ying Cheng, Jie Hu, et al. · Clinical and Translational Medicine · 1

Works count: 4

Citation count: 9

H-index: 2

I10-index: